Ptc Therapeutics (PTCT) Current Assets (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Current Assets of $2.6 billion for Q2 2026, up 15.16% year-over-year from $2.3 billion in Q2 2025, and up 16.12% quarter-over-quarter from $2.3 billion in Q1 2026.
Ptc Therapeutics (PTCT) Current Assets (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Current Assets history runs 15 years deep, the most recent figure standing at $2.6 billion for Q2 2026.
- In Q2 2026, Current Assets rose 15.16% year-over-year to $2.6 billion; the TTM figure through Jun 2026 stood at $2.6 billion (up 15.16% YoY), while the FY2025 annual figure was $2.3 billion, up 66.52% from the prior year.
- Current Assets for Q2 2026 stood at $2.6 billion, up from $2.3 billion in the prior quarter.
- The five-year high for Current Assets was $2.6 billion in Q2 2026, with the low at $517.3 million in Q3 2022.
- The 5-year median for Current Assets is $1.3 billion (2023), against an average of $1.4 billion.
- The sharpest annual moves came in 2022 and 2024: Current Assets plunged 48.84% in 2022, then soared 137.17% in 2024.
- Ptc Therapeutics' Current Assets stood at $693.8 million in 2022, then soared by 75.65% to $1.2 billion in 2023, then advanced by 12.05% to $1.4 billion in 2024, then jumped by 66.52% to $2.3 billion in 2025, then climbed by 15.1% to $2.6 billion in 2026.
- Business Quant data shows PTCT's Current Assets at $2.6 billion in Q2 2026, $2.3 billion in Q1 2026, and $2.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn | 2.62 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.62 Bn |
| Mar 31, 2026 | 2.25 Bn |
| Dec 31, 2025 | 2.27 Bn |
| Sep 30, 2025 | 2.01 Bn |
| Jun 30, 2025 | 2.27 Bn |
| Mar 31, 2025 | 2.32 Bn |
| Dec 31, 2024 | 1.37 Bn |
| Sep 30, 2024 | 1.28 Bn |
| Jun 30, 2024 | 1.36 Bn |
| Mar 31, 2024 | 1.17 Bn |
| Dec 31, 2023 | 1.22 Bn |
| Sep 30, 2023 | 540.36 Mn |
| Jun 30, 2023 | 589.69 Mn |
| Mar 31, 2023 | 613.39 Mn |
| Dec 31, 2022 | 693.79 Mn |
| Sep 30, 2022 | 517.26 Mn |
| Jun 30, 2022 | 694.68 Mn |
| Mar 31, 2022 | 774.01 Mn |
| Dec 31, 2021 | 954.37 Mn |
| Sep 30, 2021 | 1.01 Bn |